Arguments in favour of remdesivir for treating SARS-CoV-2 infections

Wen‐Chien Ko(National Cheng Kung University Hospital), Jean‐Marc Rolain(Aix-Marseille Université), Nan–Yao Lee(National Cheng Kung University), Po‐Lin Chen(National Cheng Kung University Hospital), Ching-Tai Huang(Chang Gung Memorial Hospital), Ping‐Ing Lee(National Taiwan University Hospital), Po‐Ren Hsueh(National Taiwan University Hospital)
International Journal of Antimicrobial Agents
March 5, 2020
10.1016/j.ijantimicag.2020.105933
Cited by 328Open Access
Full Text

Abstract

Related Papers

Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China
Chaolin Huang, Yeming Wang, Xingwang Li et al.|The Lancet|2020|51.8k
A Novel Coronavirus from Patients with Pneumonia in China, 2019
Na Zhu, Dingyu Zhang, Wenling Wang et al.|New England Journal of Medicine|2020|30.3k
Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study
Nanshan Chen, Min Zhou, Xuan Dong et al.|The Lancet|2020|22.7k
Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus–Infected Pneumonia
Qun Li, Xuhua Guan, Peng Wu et al.|New England Journal of Medicine|2020|17.9k
A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster
Jasper Fuk‐Woo Chan, Shuofeng Yuan, Kin‐Hang Kok et al.|The Lancet|2020|9.6k